Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs is facing a more constrained near-term outlook due to limited catalysts and tightening capital resources. Despite progress in their ongoing clinical trials for their vaccines and immunotherapies, the company's liquidity remains a concern with only $3.1M in cash at the end of 2025. As a result, the analyst lowers their rating from Buy to Hold and removes their price target, citing the elevated risk of dilutive capital raises in the future. However, upcoming milestones in regulatory engagement and the initiation of new clinical trials may provide validation for the company's pipeline in the long term.

Bears say

Geovax Labs is shifting its focus towards their lead candidate GEO-MVA and a next-generation COVID-19 vaccine, supported by the recent completion of clinical supply manufacturing and regulatory alignment. While these developments may give the company a differentiated role in the market, their limited balance sheet poses a significant financing risk. Additionally, while Gedeptin shows potential, sustained investment is needed and further dilution is likely. Beyond GEO-MVA, the company also has multiple portfolio programs approaching value-inflection points, including Gedeptin in combination with an immune checkpoint inhibitor in head and neck cancer, and their unique AGE1 continuous avian cell-line manufacturing platform.

Geovax Labs (GOVX) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Hold based on their latest research and market trends.

According to 1 analysts, Geovax Labs (GOVX) has a Hold consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.